U.S. FDA Approves Trodelvy® for First Line Treatment of Metastatic Triple Negative Breast Cancer
The U.S. FDA has approved Gilead Sciences' drug Trodelvy for the first-line treatment of metastatic triple-negative breast cancer. The approval is based on clinical trial data showing significant improvements in progression-free survival for patients.
Why it matters
This approval provides a new, critical treatment option for patients with an aggressive form of cancer where initial therapy choices are vital for long-term outcomes.
News Releases U-S--FDA-Approves-Trodelvy-for-First-Line-Treatment-of-Metastatic-Triple-Negative-Breast-Cancer June 24, 2026 U.S. FDA Approves Trodelvy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer Back – Trodelvy is a New Backbone Therapy and the Only Approved ADC in First-Line mTNBC Across PD-L1 Status –
The content is a corporate press release detailing regulatory approval, which is factual and industry-standard.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in